- Article
- Published:
Alterations of the human gut microbiome in liver cirrhosis
- Nan Qin1,2 na1,
- Fengling Yang1 na1,
- Ang Li1 na1,
- Edi Prifti3 na1,
- Yanfei Chen1 na1,
- Li Shao1,2 na1,
- Jing Guo1,
- Emmanuelle Le Chatelier3,
- Jian Yao1,2,
- Lingjiao Wu1,
- Jiawei Zhou1,
- Shujun Ni1,
- Lin Liu1,
- Nicolas Pons3,
- Jean Michel Batto3,
- Sean P. Kennedy3,
- Pierre Leonard3,
- Chunhui Yuan1,
- Wenchao Ding1,
- Yuanting Chen1,
- Xinjun Hu1,
- Beiwen Zheng1,2,
- Guirong Qian1,
- Wei Xu1,
- S. Dusko Ehrlich3,4,
- Shusen Zheng2,5 &
- …
- Lanjuan Li1,2
Naturevolume 513, pages59–64 (2014)Cite this article
61kAccesses
1952Citations
149Altmetric
Abstract
Liver cirrhosis occurs as a consequence of many chronic liver diseases that are prevalent worldwide. Here we characterize the gut microbiome in liver cirrhosis by comparing 98 patients and 83 healthy control individuals. We build a reference gene set for the cohort containing 2.69 million genes, 36.1% of which are novel. Quantitative metagenomics reveals 75,245 genes that differ in abundance between the patients and healthy individuals (false discovery rate < 0.0001) and can be grouped into 66 clusters representing cognate bacterial species; 28 are enriched in patients and 38 in control individuals. Most (54%) of the patient-enriched, taxonomically assigned species are of buccal origin, suggesting an invasion of the gut from the mouth in liver cirrhosis. Biomarkers specific to liver cirrhosis at gene and function levels are revealed by a comparison with those for type 2 diabetes and inflammatory bowel disease. On the basis of only 15 biomarkers, a highly accurate patient discrimination index is created and validated on an independent cohort. Thus microbiota-targeted biomarkers may be a powerful tool for diagnosis of different diseases.
This is a preview of subscription content,access via your institution
Access options
Subscription info for Japanese customers
We have a dedicated website for our Japanese customers. Please go tonatureasia.com to subscribe to this journal.
Prices may be subject to local taxes which are calculated during checkout



Similar content being viewed by others
References
Fouts, D. E., Torralba, M., Nelson, K. E., Brenner, D. A. & Schnabl, B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease.J. Hepatol.56, 1283–1292 (2012)
Cesaro, C. et al. Gut microbiota and probiotics in chronic liver diseases.Digest. Liver Dis.43, 431–438 (2011)
Wiest, R. & Garcia-Tsao, G. Bacterial translocation (BT) in cirrhosis.Hepatology41, 422–433 (2005)
Nolan, J. P. The role of intestinal endotoxin in liver injury: a long and evolving history.Hepatology52, 1829–1835 (2010)
Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome.Science312, 1355–1359 (2006)
Garcia-Tsao, G. & Wiest, R. Gut microflora in the pathogenesis of the complications of cirrhosis.Best Pract. Res. Clin. Gastroenterol.18, 353–372 (2004)
Wiest, R., Krag, A. & Gerbes, A. Spontaneous bacterial peritonitis: recent guidelines and beyond.Gut61, 297–310 (2012)
Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy.N. Engl. J. Med.362, 1071–1081 (2010)
Benten, D. & Wiest, R. Gut microbiome and intestinal barrier failure–the “Achilles heel” in hepatology?J. Hepatol.56, 1221–1223 (2012)
Yan, A. W. et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease.Hepatology53, 96–105 (2011)
De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa.Proc. Natl Acad. Sci. USA107, 14691–14696 (2010)
Cho, I. & Blaser, M. J. The human microbiome: at the interface of health and disease.Nature Rev. Genet.13, 260–270 (2012)
Chen, Y. et al. Characterization of fecal microbial communities in patients with liver cirrhosis.Hepatology54, 562–572 (2011)
Nelson, K. E. et al. A catalog of reference genomes from the human microbiome.Science328, 994–999 (2010)
Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity.Nature444, 1022–1023 (2006)
Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest.Nature444, 1027–1031 (2006)
Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins.Nature457, 480–484 (2009)
Ley, R. E. et al. Obesity alters gut microbial ecology.Proc. Natl Acad. Sci. USA102, 11070–11075 (2005)
Lepage, P. et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis.Gastroenterology141, 227–236 (2011)
Garrett, W. S. et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis.Cell Host Microbe8, 292–300 (2010)
Wen, L. et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes.Nature455, 1109–1113 (2008)
Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes.Nature490, 55–60 (2012)
Vijay-Kumar, M. et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5.Science328, 228–231 (2010)
Karlsson, F. H. et al. Symptomatic atherosclerosis is associated with an altered gut metagenome.Nature Commun.3, 1245 (2012)
The Human Microbiome Project Consortium A framework for human microbiome research.Nature486, 215–221 (2012)
The Human Microbiome Project Consortium Structure, function and diversity of the healthy human microbiome.Nature486, 207–214 (2012)
Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers.Nature500, 541–546 (2013)
Cotillard, A. et al. Dietary intervention impact on gut microbial gene richness.Nature500, 585–588 (2013)
Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing.Nature464, 59–65 (2010)
Nielsen, H. B. et al. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes.Nature Biotechnolhttp://dx.doi.org/10.1038/nbt.2939 (2014)
Albertsen, M. et al. Genome sequences of rare, uncultured bacteria obtained by differential coverage binning of multiple metagenomes.Nature Biotechnol.31, 533–538 (2013)
Zoetendal, E. G. et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates.ISME J.6, 1415–1426 (2012)
Bauer, T. M. et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia.Am. J. Gastroenterol.97, 2364–2370 (2002)
Chen, T. et al. The Human Oral Microbiome Database: a web accessible resource for investigating oral microbe taxonomic and genomic information.Database2010, baq013 (2010)
Pagani, I. et al. The Genomes OnLine Database (GOLD) v.4: status of genomic and metagenomic projects and their associated metadata.Nucleic Acids Res.40, D571–D579 (2012)
Saarela, M., Mogensen, G., Fonden, R., Matto, J. & Mattila-Sandholm, T. Probiotic bacteria: safety, functional and technological properties.J. Biotechnol.84, 197–215 (2000)
Merritt, M. E. & Donaldson, J. R. Effect of bile salts on the DNA and membrane integrity of enteric bacteria.J. Med. Microbiol.58, 1533–1541 (2009)
Marchandin, H. et al. Prosthetic joint infection due toVeillonella dispar.Eur. J Clin. Microbiol. Infect. Dis.20, 340–342 (2001)
Hwang, J. J., Lau, Y. J., Hu, B. S., Shi, Z. Y. & Lin, Y. H.Haemophilus parainfluenzae andFusobacterium necrophorum liver abscess: a case report.J. Microbiol. Immunol. Infect.35, 65–67 (2002)
Xu, M. et al. Changes of fecalBifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease.Microb. Ecol.63, 304–313 (2012)
Greenblum, S., Turnbaugh, P. J. & Borenstein, E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease.Proc. Natl Acad. Sci. USA109, 594–599 (2012)
Krieger, D. et al. Manganese and chronic hepatic encephalopathy.Lancet346, 270–274 (1995)
Ferenci, P., Schafer, D. F., Kleinberger, G., Hoofnagle, J. H. & Jones, E. A. Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease.Lancetii, 811–814 (1983)
Minuk, G. Y., Winder, A., Burgess, E. D. & Sarjeant, E. J. Serum gamma-aminobutyric acid (GABA) levels in patients with hepatic encephalopathy.Hepatogastroenterology32, 171–174 (1985)
Yatsunenko, T. et al. Human gut microbiome viewed across age and geography.Nature486, 222–227 (2012)
Wu, G. D. et al. Linking long-term dietary patterns with gut microbial enterotypes.Science334, 105–108 (2011)
Li, M. et al. Symbiotic gut microbes modulate human metabolic phenotypes.Proc. Natl Acad. Sci. USA105, 2117–2122 (2008)
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform.Bioinformatics25, 1754–1760 (2009)
Li, R. et al. De novo assembly of human genomes with massively parallel short read sequencing.Genome Res.20, 265–272 (2010)
Li, R. et al. SOAP2: an improved ultrafast tool for short read alignment.Bioinformatics25, 1966–1967 (2009)
Noguchi, H., Park, J. & Takagi, T. MetaGene: prokaryotic gene finding from environmental genome shotgun sequences.Nucleic Acids Res.34, 5623–5630 (2006)
Powell, S. et al. eggNOG v3.0: orthologous groups covering 1133 organisms at 41 different taxonomic ranges.Nucleic Acids Res.40, D284–D289 (2012)
Faust, K. et al. Microbial co-occurrence relationships in the human microbiome.PLOS Comput. Biol.8, e1002606 (2012)
Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies.Nature Genet.38, 904–909 (2006)
Ding, C. & Peng, H. Minimum redundancy feature selection from microarray gene expression data.J. Bioinform. Comput. Biol.3, 185–205 (2005)
Acknowledgements
This work was supported by the National Program on Key Basic Research Project (2013CB531401), the National Natural Science Foundation of China (81301475 and 81330011), the Science Fund for Creative Research Groups of the National Natural Science Foundation of China (81121002), the Technology Group Project for Infectious Disease Control of Zhejiang Province (2009R50041) and the Metagenopolis grant ANR-11-DPBS-0001. We thank Q. Cao, K. Su, J. Shao and A. Ghozlane for help with data computation, and H. Zhang, H. Lu, Q. Bao, J. Ge, J. Jiang, Z. Ren and M. Ye for assistance with sample collection. We are thankful to the MetaHIT consortium for generating the gut gene set and the Human Microbiome Project for generating the reference genomes from human gut microbes.
Author information
Nan Qin, Fengling Yang, Ang Li, Edi Prifti, Yanfei Chen and Li Shao: These authors contributed equally to this work.
Authors and Affiliations
State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China
Nan Qin, Fengling Yang, Ang Li, Yanfei Chen, Li Shao, Jing Guo, Jian Yao, Lingjiao Wu, Jiawei Zhou, Shujun Ni, Lin Liu, Chunhui Yuan, Wenchao Ding, Yuanting Chen, Xinjun Hu, Beiwen Zheng, Guirong Qian, Wei Xu & Lanjuan Li
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, 310003, China
Nan Qin, Li Shao, Jian Yao, Beiwen Zheng, Shusen Zheng & Lanjuan Li
Metagenopolis, Institut National de la Recherche Agronomique, 78350 Jouy en Josas, France,
Edi Prifti, Emmanuelle Le Chatelier, Nicolas Pons, Jean Michel Batto, Sean P. Kennedy, Pierre Leonard & S. Dusko Ehrlich
King’s College London, Centre for Host-Microbiome Interactions, Dental Institute Central Office, Guy’s Hospital, London Bridge, London SE1 9RT, UK,
S. Dusko Ehrlich
Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, the First Affiliated Hospital, Zhejiang University, Hangzhou, 310003, China
Shusen Zheng
- Nan Qin
Search author on:PubMed Google Scholar
- Fengling Yang
Search author on:PubMed Google Scholar
- Ang Li
Search author on:PubMed Google Scholar
- Edi Prifti
Search author on:PubMed Google Scholar
- Yanfei Chen
Search author on:PubMed Google Scholar
- Li Shao
Search author on:PubMed Google Scholar
- Jing Guo
Search author on:PubMed Google Scholar
- Emmanuelle Le Chatelier
Search author on:PubMed Google Scholar
- Jian Yao
Search author on:PubMed Google Scholar
- Lingjiao Wu
Search author on:PubMed Google Scholar
- Jiawei Zhou
Search author on:PubMed Google Scholar
- Shujun Ni
Search author on:PubMed Google Scholar
- Lin Liu
Search author on:PubMed Google Scholar
- Nicolas Pons
Search author on:PubMed Google Scholar
- Jean Michel Batto
Search author on:PubMed Google Scholar
- Sean P. Kennedy
Search author on:PubMed Google Scholar
- Pierre Leonard
Search author on:PubMed Google Scholar
- Chunhui Yuan
Search author on:PubMed Google Scholar
- Wenchao Ding
Search author on:PubMed Google Scholar
- Yuanting Chen
Search author on:PubMed Google Scholar
- Xinjun Hu
Search author on:PubMed Google Scholar
- Beiwen Zheng
Search author on:PubMed Google Scholar
- Guirong Qian
Search author on:PubMed Google Scholar
- Wei Xu
Search author on:PubMed Google Scholar
- S. Dusko Ehrlich
Search author on:PubMed Google Scholar
- Shusen Zheng
Search author on:PubMed Google Scholar
- Lanjuan Li
Search author on:PubMed Google Scholar
Contributions
L.J.L., S.D.E., S.S.Z. and N.Q. designed the project. L.J.L., S.P.K. and N.Q. managed the project. F.L.Y., N.Q., Y.F.C., J.G., G.R.Q., X.J.H. and B.W.Z. collected samples and performed clinical study. J.G., Y.T.C. and W.X. performed DNA extraction experiments. Y.J., L.J.W., J.W.Z. and S.J.N. performed library construction and sequencing. L.J.L. and S.D.E. designed the analysis. N.Q., A.L., E.P., E.L.C., L.L., N.P., P.L., J.M.B., C.H.Y. and W.C.D. analysed the data. A.L. and N.Q. did the functional annotation analyses. L.S., E.P., E.L.C. and A.L. analysed the statistics. N.Q., F.L.Y., L.S. and E.P. wrote the paper. L.J.L. and S.D.E. revised the paper.
Corresponding authors
Correspondence toS. Dusko Ehrlich,Shusen Zheng orLanjuan Li.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Extended data figures and tables
Extended Data Figure 1 Venn diagram comparing the current major human microbiome gene set and the results of a principal component analysis of biomarkers distributed between patients with liver cirrhosis and healthy controls.
a, Venn diagram of the four currently available major human microbiome gene sets. The total gene number in each gene set and the overlapping areas are indicated.b, Venn diagram of the three major human gut gene sets (LC, liver cirrhosis gene set; T2D, type 2 diabetes gene set; MetaHIT, MetaHIT gene set; HMP, HMP gene set).c, Visualization of the principal component analysis results for the liver-cirrhosis-associated genes that differed significantly in the discovery cohort (FDR < 0.0001, Wilcoxon rank-sum test adjusted for multiple testing). The principal component analysis is built here using these genes in the validation cohort (25 patients with liver cirrhosis in red, 31 healthy controls in green).
Extended Data Figure 2 Phylogenetic abundance at the phylum, genus and species levels from liver cirrhosis and healthy control samples.
a, Phylogenetic abundance variation box plot at the phylum level and the 30 most abundant phylotypes at the genus and species levels in the healthy controls are shown. Red, green, blue, turquoise and purple represent Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria and other phyla, respectively. The colour of each genus and species corresponds with the colour of its respective phylum.b, Phylogenetic abundance variation box plot at the phylum level and the 30 most abundant phylotypes at the genus and species levels in the liver cirrhosis are shown (see Methods for the calculations). The boxes represent the interquartile range, from the first and third quartiles, and the inside line represents the median. The whiskers denote the lowest and highest values within an interquartile range of 1.53 from the first and third quartiles. The circles represent outliers beyond the whiskers.
Extended Data Figure 3 MGS enriched in healthy Chinese individuals (n = 114) are present in Danish individuals (n = 292).
Presence and abundance of 50 ‘tracer’ genes for each species; genes are in rows; abundance is indicated by colour gradient (white, not detected; red, most abundant). Individuals, ordered by increasing gene count, are in columns. Significance of correlation of species abundance (computed as mean abundance of the tracer genes) and gene count (q value, FDR adjusted) is given. Species in the Chinese cohort that were identical to those previously found, as correlated with the gene diversity in the Danish cohort27, are highlighted in red. Left, the Chinese healthy cohort. Right, the Danish obesity cohort.
Extended Data Figure 4 Massive changes in the gut microbiome in liver cirrhosis.
Top left, healthy individuals have more gut microbial genes than patients with liver cirrhosis. Gene count was computed after downsizing the mapped reads to a level of 6.2 million (ref.27). The significance of the difference was computed using a Student’st-test. Bottom, abundance of patient-enriched species (n = 28) in patients with liver cirrhosis (n = 98) and healthy controls (n = 83). The relative abundance of each patient-enriched species was computed as a sum of the abundances of all the genes assigned to it divided by the sum of the abundances of all gut microbial genes in each patient, which is equal to 1 in the normalized data set. Bar length indicates the relative abundance of a given species depicted by a different colour. Patients were ordered by the total patient-enriched species abundance; LPA and HPA quartiles (n = 24) are separated by red vertical lines. Top right, oral species are frequent in patients with liver cirrhosis. MGS enriched in healthy controls are largely not assigned to a species level, while those enriched in patients with liver cirrhosis are largely assigned to a species level and are mostly of oral origin (see Methods for species assignment).
Extended Data Figure 5 The distribution of eggNOG orthologue group and KEGG functional categories for liver-cirrhosis-related markers.
a, Comparison between the liver-cirrhosis-enriched and control-enriched eggNOG orthologue group markers for 24 eggNOG orthologue group functional categories shown by number.b, Comparison between the liver-cirrhosis-enriched and control-enriched eggNOG orthologue group markers for 24 eggNOG orthologue group functional categories shown by percentage.c, Comparison between the liver-cirrhosis-enriched and control-enriched KEGG orthologue group markers for each KEGG functional category shown by number.d, Comparison between the liver-cirrhosis-enriched and control-enriched KEGG orthologue group markers for each KEGG functional category shown by percentage.
Extended Data Figure 6 A comparison of the gene markers for the different groups.
a, Venn diagram showing a gene marker comparison of case-enriched gene markers from the liver cirrhosis, T2D and IBD studies.b, Venn diagram showing a gene marker comparison of control-enriched gene markers from the liver cirrhosis, T2D and IBD studies.c, The length of the bar (y axis) represents the number of genes; theP value in the related range is shown on thex axis. The pink and light green bars show genes involved in type 2 diabetes and liver cirrhosis, respectively. Inset, the logP value of the gene markers between the two studies.
Extended Data Figure 7 The distribution of eggNOG functional categories for case-enriched and control-enriched gene markers in liver cirrhosis only, T2D only and the liver cirrhosis/T2D groups.
a, Comparison of the eggNOG orthologue group functional categories for case-enriched gene markers shown by number.b, Comparison of the eggNOG orthologue group functional categories for case-enriched gene markers shown by percentage.c, Comparison of the eggNOG orthologue group functional categories for the control-enriched gene markers shown by number.d, Comparison of the eggNOG orthologue group functional categories for the control-enriched gene markers shown by percentage.
Extended Data Figure 8 The distribution of the KEGG functional categories for case-enriched and control-enriched gene markers in liver cirrhosis only, T2D only or the liver cirrhosis/T2D group.
a, Comparison of the KEGG pathway categories for the case-enriched gene markers shown by number.b, Comparison of the KEGG pathway categories for the case-enriched gene markers shown by percentage.c, Comparison of the KEGG pathway categories for the control-enriched gene markers shown by number.d, Comparison of the KEGG pathway categories for the control-enriched gene markers shown by percentage.
Extended Data Figure 9 Estimating the optimum number of markers and establishing the taxonomic assignment of MGS.
a, Comparison of the case-enriched gene markers.b, Comparison of the control-enriched gene markers.c, The mRMR method was used to identify the liver-cirrhosis-associated markers. Sequential subsets were generated at five-marker intervals. For each subset, the error rate was estimated using a leave-one-out cross-validation of a linear discrimination classifier. The optimum (highest value of the Matthews correlation coefficient) subset contains 15 gene markers.d, The study included a discovery and a validation phase. Volunteers for both phases were recruited in the same hospital. Both direct read mapping andde novo assembly were performed for each sample. A taxonomy profiling table was established for taxonomy analysis. A novel gut gene set was established, and annotated. Identification of the MGS, finding markers and validating markers is also shown.e, MGS enriched in Chinese patients with liver cirrhosis and healthy individuals. Species-level assignment was deduced from the best BlastN hits of genes from a given MGS at thresholds of the average of more than 95% identity and more than 90% overlap with genes from a sequenced genome. For MGS where these thresholds were not reached, an assignment was attributed at the lowest taxonomy level where at least 80% of the genes had the same best hit BlastP taxonomy; in all cases these criteria held true at higher taxonomic levels.f, Taxonomic assignments of 58 species related to gut gene richness in a Danish cohort27.
Extended Data Figure 10 Phylogenetic abundance of healthy controls in the discovery stage in the liver cirrhosis and T2D studies.
The relative abundance of top bacterial phylotypes at the phylum, genus and species levels, respectively, in the liver cirrhosis study (top three panels) and in the T2D study (bottom three panels).
Supplementary information
Supplementary Information
This zipped file contains Supplementary Tables 1-15 and a Supplementary Table guide. (ZIP 2789 kb)
Rights and permissions
About this article
Cite this article
Qin, N., Yang, F., Li, A.et al. Alterations of the human gut microbiome in liver cirrhosis.Nature513, 59–64 (2014). https://doi.org/10.1038/nature13568
Received:
Accepted:
Published:
Issue date:
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
This article is cited by
Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites
- Jiahui Luan
- Fuxin Zhang
- Hongyun Cao
BMC Pulmonary Medicine (2024)
Multi-kingdom microbial signatures in excess body weight colorectal cancer based on global metagenomic analysis
- Xinyue Zhu
- Pingping Xu
- Na Jiao
Communications Biology (2024)
APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure
- Rakhi Maiwall
- Satender Pal Singh
- Shiv Kumar Sarin
Hepatology International (2024)
Integrative analysis of the gut microbiota and faecal and serum short-chain fatty acids and tryptophan metabolites in patients with cirrhosis and hepatic encephalopathy
- Qiang Wang
- Chengxin Chen
- Haiyang Li
Journal of Translational Medicine (2023)
Transmission of oral microbiota to the biliary tract during endoscopic retrograde cholangiography
- Maria Effenberger
- Ramona Al-Zoairy
- Heinz Zoller
BMC Gastroenterology (2023)


